RETRACTED: FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance (Retracted Article)

被引:27
作者
Intuyod, Kitti [1 ,2 ,3 ]
Saavedra-Garcia, Paula [1 ]
Zona, Stefania [1 ]
Lai, Chun-Fui [1 ]
Jiramongkol, Yannasittha [1 ]
Vaeteewoottacharn, Kulthida [3 ,4 ]
Pairojkul, Chawalit [3 ,5 ]
Yao, Shang [1 ]
Yong, Jay-Sze [1 ]
Trakansuebkul, Sasanan [1 ]
Waraasawapati, Sakda [3 ,5 ]
Luvira, Vor [3 ,6 ]
Wongkham, Sopit [3 ,4 ]
Pinlaor, Somchai [3 ,7 ]
Lam, Eric W. -F. [1 ]
机构
[1] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England
[2] Khon Kaen Univ, Grad Sch, Biomed Sci Program, Khon Kaen 40002, Thailand
[3] Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen 40002, Thailand
[4] Khon Kaen Univ, Dept Biochem, Fac Med, Khon Kaen 40002, Thailand
[5] Khon Kaen Univ, Dept Pathol, Fac Med, Khon Kaen 40002, Thailand
[6] Khon Kaen Univ, Dept Surg, Fac Med, Khon Kaen, Thailand
[7] Khon Kaen Univ, Dept Parasitol, Fac Med, Khon Kaen, Thailand
基金
英国医学研究理事会;
关键词
NITRATIVE DNA-DAMAGE; OPISTHORCHIS-VIVERRINI; BREAST-CANCER; INTRAHEPATIC CHOLANGIOCARCINOMA; GENE-EXPRESSION; DIAGNOSIS; E2F1; REGULATOR; PROFILES; FIBROSIS;
D O I
10.1038/s41419-018-1235-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Fluorouracil (5-FU) is the first-line chemotherapeutic drug for cholangiocarcinoma (CCA), but its efficacy has been compromised by the development of resistance. Development of 5-FU resistance is associated with elevated expression of its cellular target, thymidylate synthase (TYMS). E2F1 transcription factor has previously been shown to modulate the expression of FOXM1 and TYMS. Immunohistochemical (IHC) analysis revealed a strong correlated upregulation of FOXM1 (78%) and TYMS (48%) expression at the protein levels in CCA tissues. In agreement, RT-qPCR and western blot analyses of four human CCA cell lines at the baseline level and in response to high doses of 5-FU revealed good correlations between FOXM1 and TYMS expression in the CCA cell lines tested, except for the highly 5FU- resistant HuCCA cells. Consistently, siRNA-mediated knockdown of FOXM1 reduced the clonogenicity and TYMS expression in the relatively sensitive KKU-D131 but not in the highly resistant HuCCA cells. Interestingly, silencing of TYMS sensitized both KKU-D131 and HuCCA to 5-FU treatment, suggesting that resistance to very high levels of 5-FU is due to the inability of the genotoxic sensor FOXM1 to modulate TYMS expression. Consistently, ChIP analysis revealed that FOXM1 binds efficiently to the TYMS promoter and modulates TYMS expression at the promoter level upon 5-FU treatment in KKU-D131 but not in HuCCA cells. In addition, E2F1 expression did not correlate with either FOXM1 or TYMS expression and E2F1 depletion has no effects on the clonogenicity and TYMS expression in the CCA cells. In conclusion, our data show that FOXM1 regulates TYMS expression to modulate 5-FU resistance in CCA and that severe 5-FU resistance can be caused by the uncoupling of the regulation of TYMS by FOXM1. Our findings suggest that the FOXM1-TYMS axis can be a novel diagnostic, predictive and prognostic marker as well as a therapeutic target for CCA.
引用
收藏
页数:15
相关论文
共 50 条
[1]   Diagnosis and treatment of cholangiocarcinoma [J].
Anderson, CD ;
Pinson, CW ;
Berlin, J ;
Chari, RS .
ONCOLOGIST, 2004, 9 (01) :43-57
[2]   Pro-proliferative FoxM1 is a target of p53-mediated repression [J].
Barsotti, A. M. ;
Prives, C. .
ONCOGENE, 2009, 28 (48) :4295-4305
[3]   Surgical treatment for intrahepatic cholangiocarcinoma in Europe: a single center experience [J].
Bektas, Hueseyin ;
Yeyrek, Cemil ;
Kleine, Moritz ;
Vondran, Florian W. R. ;
Timrott, Kai ;
Schweitzer, Nora ;
Vogel, Arndt ;
Jaeger, Mark D. ;
Schrem, Harald ;
Klempnauer, Juergen ;
Kousoulas, Lampros .
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2015, 22 (02) :131-137
[4]   Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer [J].
Burdelski, Christoph ;
Strauss, Christian ;
Tsourlakis, Maria Christina ;
Kluth, Martina ;
Hube-Magg, Claudia ;
Melling, Nathaniel ;
Lebok, Patrick ;
Minner, Sarah ;
Koop, Christina ;
Graefen, Markus ;
Heinzer, Hans ;
Wittmer, Corinna ;
Krech, Till ;
Sauter, Guido ;
Wilczak, Waldemar ;
Simon, Ronald ;
Schlomm, Thorsten ;
Steurer, Stefan .
ONCOTARGET, 2015, 6 (10) :8377-8387
[5]   Histological confirmation of periductal fibrosis from ultrasound diagnosis in cholangiocarcinoma patients [J].
Chamadol, Nittaya ;
Pairojkul, Chawalit ;
Khuntikeo, Narong ;
Laopaiboon, Vallop ;
Loilome, Watcharin ;
Sithithaworn, Paiboon ;
Yongvanit, Paungrat .
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2014, 21 (05) :316-322
[6]   The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets [J].
Chong, Dawn Q. ;
Zhu, Andrew X. .
ONCOTARGET, 2016, 7 (29) :46750-46767
[7]  
Chu E, 1999, MOL CELL BIOL, V19, P1582
[8]   THYMIDYLATE SYNTHASE GENE AMPLIFICATION IN HUMAN COLON-CANCER CELL-LINES RESISTANT TO 5-FLUOROURACIL [J].
COPUR, S ;
AIBA, K ;
DRAKE, JC ;
ALLEGRA, CJ ;
CHU, E .
BIOCHEMICAL PHARMACOLOGY, 1995, 49 (10) :1419-1426
[9]   The p38 MAPK-MK2 Axis Regulates E2F1 and FOXM1 Expression after Epirubicin Treatment [J].
de Olano, Natalia ;
Koo, Chuay-Yeng ;
Monteiro, Lara J. ;
Pinto, Paola H. ;
Gomes, Ana R. ;
Aligue, Rosa ;
Lam, Eric W. -F. .
MOLECULAR CANCER RESEARCH, 2012, 10 (09) :1189-1202
[10]   E2F1, a Novel Regulator of Metabolism [J].
Denechaud, Pierre-Damien ;
Fajas, Lluis ;
Giralt, Albert .
FRONTIERS IN ENDOCRINOLOGY, 2017, 8